Aims: We previously demonstrated that intrathecal IL-1β upregulated phosphorylation of p38 mitogen-activated protein kinase (P-p38 MAPK) and inducible nitric oxide synthase (iNOS) in microglia and astrocytes in spinal cord, increased nitric oxide (NO) release into cerebrospinal fluid, and induced thermal hyperalgesia in rats. This study investigated the role of spinal glutamatergic response in intrathecal IL-1β-induced nociception in rats.
| INTRODUCTION
Glutamate functions as neurotransmitter and its extracellular concentration is normally low in the central nervous system (CNS). It activates glutamate receptors and plays a significant role in nociception.
Glutamate transporters (GTs), including glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT-1), and excitatory amino acid carrier-1 (EAAC1), remove glutamate from the synapses and maintain glutamatergic homeostasis. Elevated glutamate concentration caused by either excessive release or decreased uptake associates with pain 1 and glutamate administration produces pain. 2 The N-methyl-Daspartate (NMDA) receptors are glutamate receptors composed of NR1 subunits, and activation of NMDA receptor (NMDAR) by phosphorylating NR1 (p-NR1) is important in nociceptive processing and correlates with pain. [3] [4] [5] [6] Animal studies on nociception have revealed upregulation of p-NR1 in dorsal root ganglion (DRG) neurons and primary afferent fibers, 7 postsynaptic neurons, 8, 9 microglia, 8 and astrocytes 9 in the spinal cord dorsal horn (SCDH). In addition, activation of presynaptic NMDARs increases glutamate release and excitatory postsynaptic currents (EPSC) in DRG neurons of rats with ligated spinal nerves.
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However, p-NR1 expression in rat DRG neurons decreases following intraplantar injection with complete Freund's adjuvant (CFA).
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Activation of astrocytes and microglia is associated with increased TNF-α expression, reduced expression of GLAST, GLT-1, and EAAC1
in SCDH, and elevated glutamate level in CSF in rats with sciatic nerve injury. 12 GLT-1 downregulation occurs in activated astrocytes in rat models of morphine-tolerant pain, peripheral neuropathic pain, and experimental autoimmune encephalomyelitis, whereas intrathecal ceftriaxone and MK-801 abolish these responses. 13, 14 In contrast, inhibition of GLT-1 and GLAST reduces nociception and glutamate concentrations in CSF in rats receiving intraplantar injection of formalin. 15, 16 IL-1β involves in the initiation and maintenance of pain, and its levels in CSF and SCDH significantly increase 2-3 hours after intraplantar injection of CFA and lipopolysaccharide in rodents. 17, 18 Our previous studies showed that intrathecal IL-1β increases p38 mitogen-activated protein kinase phosphorylation (P-p38 MAPK) and inducible nitric oxide synthase (iNOS) in astrocytes and microglia in SCDH, releases nitric oxide (NO) in CSF, and induces thermal hyperalgesia in rats. 19, 20 In contrast, we previously had reported that pretreatment with inhibitors of microglia (minocycline), astrocytes (fluorocitrate), IL-1 receptor (IL1ra), and p38 MAPK (SB203580) suppresses the IL-1β-induced P-p38/ iNOS/NO signaling and hyperalgesia. 19, 20 As endogenous IL-1β upregulates p-NR1 that colocalize with IL-1 receptor type I (IL-1RI) in spinal neurons, IL-1 receptor antagonist (IL-1ra) inhibits the expression of p-NR1 and hyperalgesia in rat model of inflammatory pain. 21 However, the roles of glutamate, NMDAR, and GTs in intrathecal IL-1β-induced thermal hyperalgesia are not well characterized.
This study is a continuation of our preceding ones in a rat model of intrathecal IL-1β-induced thermal hyperalgesia, 19, 20 and we hypothesized that exogenous IL-1β may activate NMDAR and inhibit GTs in the spinal cord (SC) and this glutamatergic response participates in intrathecal IL-1β-induced nociceptive signaling. The aim of this study was 3-fold: to investigate (i) the spinal glutamatergic response after IL-1β injection; (ii) the interaction between glutamatergic response and P-p38/iNOS/NO signaling; and (iii) the intercellular interactions in SCDH related to IL-1β-induced nociception.
| MATERIALS AND METHODS

| Animal preparation and intrathecal drug delivery
All experiments were approved by the Institutional Animal Care and Use Committee of Taipei Veterans General Hospital, and the use of animals conformed to the Guiding Principles for the Care and Use of Animals published by the American Physiological Society. All efforts were made to minimize the number of animals used and their suffering.
Preparation of the intrathecal catheter, microdialysis probe, and animals was as previously described. 19, 20 Adult male Wistar rats (260-320 g; BioLASCO Taiwan Co., Taipei, Taiwan) were anesthetized with 2%-3% inhaled isoflurane, and an intrathecal catheter was implanted with or without a microdialysis probe. Postoperative care included subcutaneous amoxicillin (150 mg/kg) and lidocaine infiltration. Rats were allowed to recover for 4 days before experimentation, housed individually, given food and water ad libitum, and maintained on a standard 12-hours light/dark schedule at room temperature. The intrathecal catheter and microdialysis tubes were perfused with artificial CSF (aCSF) every other day to prevent obstruction. Rats with locomotor dysfunction were excluded from the study.
On day 5 after intrathecal catheterization, all drugs were administered through the intrathecal catheter, followed by a 10-μL flush with aCSF. Rats were randomly assigned to one of six groups: (i) control rats were based on previous studies. 19, 20, 22 All experimenters were blinded to the group allocations except the one who injected the drugs.
| Nociceptive behavioral assessment
Paw withdrawal latency (PWL) to radiant heat applied to the right hindpaw (Ugo Basile Biological Instruments, Comerio, Italy) was assessed as previously described. 19, 20 The heat intensity was adjusted to obtain an average PWL of 17.6±0.4 seconds, and the cutoff time was set at 22±0.4 seconds to prevent tissue damage. Paw withdrawal latency was assessed at baseline and different times after drug injection.
| Analysis of nitric oxide and glutamate in spinal CSF dialysates
A CMA102 microinfusion pump with a gastight Hamilton syringe was used to continuously perfuse aCSF through one end of the microdialysis probe at a rate of 5 μL/min, and the other end was used to collect CSF dialysates. 
| Western blotting
The dorsal part of lumbar SC enlargement was collected by exsanguination under isoflurane anesthesia at 30 minutes or 6 hours after drug injection. The Western blotting analysis was performed as described previously in refs. 19, 20 The polyvinylidene difluoride membranes 
| Immunohistochemical assay
Lumbar SC enlargement was subjected to immunohistochemical analysis. Cell markers for neurons (NeuN), astrocytes (glial fibrillary acidic protein, GFAP), and microglia (CD11b) were used to determine cellular colocalization with p-NR1. p-NR1 expression was assessed at 30 minutes (four rats per group) and 6 hours (four rats per group), and GTs expression was assessed at 6 hours (four rats per group).
The immunohistochemical analysis was performed as described previously in ref. 20 The sample was cut into 20-μm sections on a cryostat at −25°C, mounted serially onto microscope slides, and 
| Drug preparation
Recombinant rat IL-1β (R&D Systems, Minneapolis, MN, USA), MK-801 (Dizocilpine hydrogen maleate; Sigma-Aldrich®), minocycline (Sigma-Aldrich®), and SB203580 (Calbiochem, La Jolla, CA, USA)
were dissolved in sterile 0.9% physiological saline at a concentration of 50 ng/μL, 1 μg/μL, 2 μg/μL, and 1 μg/μL, respectively. Each drug was freshly prepared on the morning of the experiment. 
| Statistical analysis
| RESULTS
| Effect of MK-801 pretreatment on IL-1β-induced thermal hyperalgesia
We initially examined the role of the spinal glutamatergic response in IL-1β-induced nociception by examining the pretreatment effect of MK-801 before IL-1β injection (Figure 1) These results demonstrate that MK-801 pretreatment suppresses IL-1β-induced thermal hyperalgesia, and suggest the NMDAR involves in IL-1β-induced nociception.
| IL-1β upregulates NR1 phosphorylation in neurons and microglia, and SB203580 and minocycline pretreatment abolish the effect of IL-1β on p-NR1
Immunohistochemistry experiments showed that control rats had very low expression of p-NR1 in SCDH at 30 minutes (Figure 2A ). IL-1β dramatically upregulated NR1 phosphorylation from 30 minutes to 6 hours compared to controls (15.6-and 31.9-fold, respectively; both P<.05) (Figure 2A,d ). Double immunofluorescent staining showed that p-NR1-immunofluorescence in SCDH was not totally colocalized with neurons, microglia, and astrocytes in this study ( Figure 2B ). We fo- ( Figure 2D ). These results suggest that IL-1β primarily upregulates p-NR1 expression in neurons of SCDH.
| Effect of drug pretreatments on IL-1β-induced downregulation of GLAST, GLT-1, and EAAC1
Additional immunohistochemistry studies indicated that the immunoreactivities of GLAST, GLT-1, and EAAC1 were abundantly located in the control rats but decreased at 6 hours after IL-1β injection in SCDH ( Figure 3A) . These results are consistent with the results of Western blotting, which showed that IL-1β decreased GLAST by 60.9%, GLT-1 by 55.0%, and EAAC1 by 39.8% (P<.05 for all; Figure 3B -D). The Western blotting experiments also showed that MK-801 alone had no significant effect on these GTs expression, but pretreatment with MK-801, minocycline, and SB203580 blocked the effect of IL-1β (P<.001 for all; Figure 3B ). Similar to the effect of MK-801 on glutamate transporters, both minocycline and SB203580 alone did not affect the protein expression of GLAST, GTL-1, and EAAC1 as compared to the saline-injected controls in our studies (data not show).
F I G U R E 1 Effect of IL-1β, MK-801
, and MK-801+IL-1β on thermal hyperalgesia in rats. Paw withdrawal latency (PWL) was measured in rats given intrathecal saline (control, n=8), IL-1β (IL, n=8), MK-801 alone (MK, n=8), or MK-801 at 1 h before IL-1β (MK+IL, n=12). All values were normalized to the baseline (100%) and expressed as means±SEMs. *P<.05 relative to controls; #P<.05 relative to IL-1β; †P<.05 relative to baseline
| Effect of drug pretreatments on IL-1β-induced glutamate release into the CSF
IL-1β injection markedly increased glutamate concentration in CSF dialysates starting at 2 hours (57% increase), with a maximum at 5.5-6 hours (132%-133% increase), and an increase of 113% till 12 hours (P<.05 for all; Figure 4A ). MK-801 alone did not affect the glutamate concentration, but MK-801 pretreatment prevented the IL-1β-induced glutamate release from 1.5-12 hours (P<.05 for all; Figure 4A ). Although minocycline and SB203580 pretreatment also prevented IL-1β-induced glutamate release, minocycline did not reduce the glutamate level within 1.5-3.5 hours after IL-1β injection ( Figure 4B ).
| Effect of MK-801 on IL-1β-induced P-p38/ iNOS/NO signaling
We also examined the effect of MK-801 on IL-1β-induced NO release into the CSF. The results indicate that IL-1β increased the NO level in CSF dialysates starting at 4 hours (44% increase), with a maximum at 6 hours (156% increase), and an increase of 101% at 12 hours (P<.05 for all; Figure 5A ). MK-801 alone had no effect, but MK-801 pretreatment significantly attenuated the IL-1β-induced NO release from 
| DISCUSSION
This study demonstrated that IL-1β activates spinal neurons and microglia with upregulated p-NR1 expression, downregulates GTs, and increases extracellular glutamate level. MK-801 pretreatment not only reverses these glutamatergic responses but also inhibits the IL-1β-activated P-p38/iNOS/NO signaling and thermal hyperalgesia.
Pretreatment with minocycline or SB203580 abolishes the effect of IL-1β on glutamate release and GTs expression, but not the upregulated p-NR1. Taken together, these results indicate that both NMDAR/ GTs/glutamate and the P-p38/iNOS/NO signaling play pivotal roles in IL-1β-induced thermal hyperalgesia. IL-1β upregulates p-NR1 expression majorly in neurons and minorly in microglia and activates P-p38/ iNOS/NO signaling in microglia and astrocytes. An earlier NMDARdependent followed by a later P-p38 MAPK-dependent nociceptive signaling in neuron-glia interaction in SCDH may be responsible for the intrathecal IL-1β-induced thermal hyperalgesia.
Significant upregulation of endogenous IL-1β has been demonstrated in many models of nociception, 17, 21 and application of exogenous IL-1β produces nociception. 19, 20 IL-1β binds to the IL-1RI to produce its effect, 23 and IL-1ra completely reverses the IL-1β-induced nociceptive signaling and behaviors in rats. 19 IL-1RIs ubiquitously express in gray and white matters of SC and in neurons, astrocytes, microglia, and oligodendrocytes. 24 We previously demonstrated that intrathecal IL-1β activated microglia and astrocytes in SCDH with 
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NMDA upregulates P-p38 MAPK expression in spinal microglia and neurons and induces hyperalgesia through a P-p38-dependent way in rats with streptozotocin-induced diabetes, while MK-801 inhibits them.
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Our present study shows that MK-801, minocycline, and SB203580
all reduce the IL-1β-induced glutamatergic response; MK-801 is the most potent followed by SB203580 and minocycline in descending order. MK-801 inhibits NMDAR and increases GTs expression, and ishes the IL-1β-induced P-p38/iNOS/NO signaling and glutamatergic response, while SB203580 inhibits P-p38 upregulation and reverses
GTs downregulation without inhibiting effect on NMDAR activation.
Therefore, it suggests that the upregulated NMDAR expression is upstream of p38 and contributes to the IL-1β-activated P-p38/iNOS/ NO signaling. In addition, the P-p38/iNOS/NO pathway retrogradely enhances glutamate release. In contrast, minocycline inhibits microglia and astrocytes but not neurons. Although minocycline reverses both the downregulated GTs and activated P-p38/iNOS/NO signaling, it does not reduce the glutamate level within 1.5-3.5 hours after IL-1β
injection. It may indicate that intrathecal IL-1β activates neurons, microglia, and astrocytes and/or the primary afferents to release glutamate in a time-dependent manner, with a prominent role of neurons in the early phase (within 3.5 hours) and of microglia in the late phase.
Furthermore, the IL-1β-induced NMDAR activation and glutamate release potentiate the P-p38/iNOS/NO signaling.
Our present and previous studies showed that intrathecal IL-1β activated p-NR1 in neurons and microglia and upregulated P-p38
MAPK and iNOS in microglia and astrocytes. receptor initiates glutamate response that leads to activation of P-p38
MAPK-dependent nociceptive signaling in microglia.
Based on the timeline of the measured responses, it appears that IL-1β-induced thermal hyperalgesia is initially NMDAR-dependent, followed by a P-p38 MAPK-dependent pathway. IL-1β activates spinal microglia through both the NMDAR-and p38 MAPK-dependent pathways. In contrast, it activates neurons through the NMDARdependent pathway but activates astrocytes through the p38 MAPKdependent pathway.
| CONCLUSIONS
A complex neuron-glia interaction and distinct molecular mechanisms in SCDH underlie the intrathecal IL-1β-evoked thermal hyperalgesia in rats. We suggest that pharmacological intervention that disrupts these specific targets may be suitable for clinical pain management.
